Mechanism: upstream of growth hormone
Tesamorelin binds GHRH receptors on the anterior pituitary, stimulating endogenous growth hormone release. Because GH is released in a natural pulse, the body's feedback loop stays intact — IGF-1 rises into a physiological range rather than the supraphysiological spike seen with direct GH injection.
Visceral fat reduction
Tesamorelin is the only GHRH analog with FDA-approved data for reducing visceral adipose tissue (VAT). Trials in HIV-associated lipodystrophy showed ~15–20% VAT reduction at 2 mg daily over 26 weeks. Subsequent research has examined the same effect in metabolic syndrome and non-alcoholic fatty liver disease.
Cognition and lean body composition
Studies have shown improvements in executive function in older adults at risk for cognitive decline, attributed to elevated IGF-1 in the CNS. Lean body mass typically increases 1–2 kg over a 6-month research protocol, with improvements in lipid panel (lower triglycerides, higher HDL).
Dosing and protocol
Research dosing is 1–2 mg subcutaneous, once daily before bed to align with the natural GH pulse. Half-life is short (~26 minutes), so the peptide is cleared quickly but the GH pulse it triggers persists for hours. Effects on body composition typically appear at the 8–12 week mark.